Boston Scientific completes enrolment for Synergy stent trial

Boston Scientific has completed patient enrolment for a new study of its Synergy drug-eluting coronary stent.

A total of 291 subjects from across Europe, Australia and New Zealand have been recruited for the upcoming Evolve trial, which will compare the efficacy of Synergy to the company's own Promus Element stent among patients with a single de novo native coronary artery lesion.

Enrolment for this trial has been completed four months ahead of schedule, with Boston Scientific intending to use data from the study to support CE Mark approval of the device.

The company believes Synergy can provide the same level of restenosis reduction as a conventional drug-eluting stent, while offering faster and more complete vessel healing.

Hank Kucheman, executive vice-president and president of Boston Scientific's cardiology, rhythm and vascular group, said: "Completion of enrolment brings our fourth-generation drug-eluting stent platform another step closer to commercialisation."

Last week, Boston Scientific announced plans to purchase Atritech, the manufacturer of the atrial appendage closure device Watchman.